OncoVeryx-F is a patented technology that combines metabolomics and artificial intelligence to detect early cancers
PredOmix, a health technology pioneer and innovation-driven company, unveiled one of its kind innovative cancer detection blood test, OncoVeryx-F, capable of detecting early-stage cancers in women with a 98 per cent accuracy. Backed by advanced metabolomics technology coupled with AI, the new-age innovation will enable the screening for early-stage cancers. Designed for women, the screening tool accurately diagnoses cancer before tumour development begins.
OncoVeryx-F is a patented technology that combines metabolomics and artificial intelligence to detect early cancers. It is a blood-based screening approach that accurately identifies four major female-specific malignancies in a single blood test: breast, endometrium, cervix, and ovary. This is one of the first of its kind multi-cancer early detection (MCED) blood test developed by PredOmix that is now available in India and will aid in determining the presence or absence of cancer as well as the tissue of origin or cancer type.
Dr Kanury V S Rao, Co-Founder & Chief Scientific Officer (CSO), PredOmix, said, “Our cancer screening test’s accuracy rates are over 98 per cent. OncoVeryx-F has an extremely high specificity for detecting early stages of cancer from a very small quantity of blood samples. We have been successful in demonstrating outcomes for four women cancers including breast cancer and even ovarian cancers which are known to be a silent killer.” The company has plans to expand its testing capabilities by 2023 for detecting 17 types of cancers in both men and women.
Dr Pravin Poddar, Scientific Advisor PredOmix, says, “It’s a non-intrusive technique without any preliminary requirements of biopsy. This innovation will help find the location of the cancer cells’ growth alongside detecting cancer onset without using invasive techniques. Early diagnosis can aid timely treatment-related decisions and potentially save lives.”
